

LA JOLLA PHARMACEUTICAL CO

Form 8-K

March 02, 2004

**Table of Contents**

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549**

---

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): March 2, 2004

**LA JOLLA PHARMACEUTICAL COMPANY**

---

(Exact Name of Registrant as Specified in Charter)

Delaware

---

(State or Other Jurisdiction  
of Incorporation)

0-24274

---

(Commission  
File Number)

33-0361285

---

(IRS Employer  
Identification No.)

6455 Nancy Ridge Drive  
San Diego, California 92121  
(Address of Principal Executive Offices, Including Zip Code)

Registrant's telephone number, including area code: (858) 452-6600

---

---

---

**TABLE OF CONTENTS**

Item 12. Results of Operations and Financial Condition.

SIGNATURES

EXHIBIT INDEX

EXHIBIT 99.1

---

**Table of Contents**

**Item 12. Results of Operations and Financial Condition.**

In a press release on March 2, 2004, La Jolla Pharmaceutical Company announced and commented on its financial results for its fourth quarter and year ended December 31, 2003. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. The press release is being furnished to the Securities and Exchange Commission under Item 12. Results of Operations and Financial Condition.

The information in this Form 8-K and the exhibit attached hereto and incorporated herein shall not be deemed filed for purposes of the Securities Exchange Act of 1934, as amended (the Exchange Act ), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

---

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 2, 2004

LA JOLLA PHARMACEUTICAL  
COMPANY

By: /s/ Steven B. Engle  
Steven B. Engle  
Chairman and Chief Executive Officer

---

**Table of Contents**

**EXHIBIT INDEX**

<b><u>Exhibit Number</u></b>	<b><u>Description of Exhibit</u></b>
99.1	Press Release (furnished pursuant to Item 12. of Form 8-K)